ALS Alert mastheadALS Alert mastheadWinter 2002 - Science. Scope. Speed

ALS Center Web Site
Research
People and Events

In This Issue:

Celebrex: Let the Trials Begin
It’s good for arthritis, it’s under study for Alzheimer’s, and last month, national trials got under way exploring the anti-inflammation drug Celebrex as a possible ALS therapy. At the Center for ALS Research and 24 other sites, volunteers in early stages of the disease have begun receiving daily high doses.

Sponging Up Glutamate? Good Idea
A new study by Center scientist Margaret Sutherland, Ph.D., not only shores up a long-held idea on a major source of cell damage in ALS but also shows something can be done to fix it, at least in mice.

An Eye on the Shore
Centerwide stem cell research keeps hopes afloat in its early stages. But so far, every study answers questions that lead to more.

The New Rat Model: Bigger Is Better
A new rat model of the disease that’s far easier to work with and more versatile than earlier mouse models.

Available Issues:

Winter 2001/2002
Fall 2002
Spring 2003
Fall 2003
Spring 2004
Fall 2004
Winter 2005
Spring/Summer 2005
Fall 2005
Winter 2006

About ALS Alert


Vantage Point

photo - Jeffrey D. Rothstein, M.D., Ph.D.  
Jeffrey D. Rothstein, M.D., Ph.D.

One of the most satisfying things about directing the Center has been watching the shift in our thinking about the biology of ALS. The change has been gradual but sure—with much of it coming from work from the Center’s member laboratories worldwide. Because the shift opens new targets for therapy, that’s all the more exciting. We describe several of the studies in this first edition of ALS Alert.

Traditional ideas on ALS suggest problems lie exclusively in motor neurons.

But a couple of things have made us waver, things that called our attention to the cells— astrocytes—that surround motor neurons. Several years ago, for example, our Hopkins labs showed that ALS patients’ astrocytes don’t clear the neurotransmitter glutamate efficiently from nerve tissues.

Now we’ve found that astrocytes apparently become abnormal before motor neurons do. The clincher is Margaret Sutherland’s work that shows “fixing” flaws in astrocytes brings a huge increase in mouse survival.

Do we know what causes ALS? No. But we now realize that mere “bystander” cells are important. Astrocytes aren’t as downstream as we thought. So we’re shifting our therapeutic approach to include tactics that boost astrocyte function, including drugs like Celebrex and stem cells.

Over the next few months, I will tell you about projects under way at the Center, including new stem cell work, studies on novel proteins that might be responsible for motor neuron death, and new ideas about how a mutant version of the enzyme SOD may slow the disease.

All of this edges toward our goal—finding new therapies to stop or reverse ALS.

Jeffrey D. Rothstein, M.D., Ph.D.
Director, The Robert Packard Center
for ALS Research

   

Next > On Center: Fund-Raisers’ Bounty Keeps Center on Track
It’s a rare foundation that doesn’t have to depend on fund raising. With the Center for ALS Research, dedicated as it is to a high volume and a rapid turnout of lab results, benefits and such events are crucial. But even for this stepped-up place, the pace has been fast.









Sign up for ALS news, the print version of the newsletter and more:
   
Special Features:

Vantage point
One of the most satisfying things about directing the Center has been watching the shift in our thinking about the biology of ALS.

On Center: Fund-Raisers’ Bounty Keeps Center on Track
It’s a rare foundation that doesn’t have to depend on fund raising. With the Center for ALS Research, dedicated as it is to a high volume and a rapid turnout of lab results, benefits and such events are crucial. But even for this stepped-up place, the pace has been fast.

Insider’s View
Daniel Drachman, M.D., is a longtime Hopkins neurologist / researcher who specializes in neuromuscular diseases. In this column he answers questions.

From the Clinic
Lora Clawson, M.S.N., C.R.N.P., manages Johns Hopkins’ ALS clinic. She also oversees its clinical trials. In this column she answers typical patients’ questions.

A Friend Indeed: Orioles Hit Home Runs for ALS
With the Orioles and ALS research, the connection was serendipity. Everything just fell into place the summer of 1995, when Oriole great Cal Ripken was on the verge of breaking Lou Gehrig’s consecutive-games-
played record.

Being resourceful
Links to useful information

Make a Donation



© Copyright 2002 | All Rights Reserved | Robert Packard Center for ALS Research at Johns Hopkins
600 N. Wolfe Street, Meyer 6-109, Baltimore, Maryland 21287-5953 USA
Site Index Frequently Asked Questions Contact Us Hopkins Medicine